These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 3265609)

  • 1. Acetylation phenotypes in patients with bladder carcinoma.
    Bicho MP; Breitenfeld L; Carvalho AA; Manso CF
    Ann Genet; 1988; 31(3):167-71. PubMed ID: 3265609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic acetylator phenotype in bladder cancer patients.
    Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
    Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The acetylator phenotype in patients with urinary bladder cancer].
    Wich H; Franke G; Grimm U; Siegmund W
    Z Urol Nephrol; 1989 Nov; 82(11):597-9. PubMed ID: 2618184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
    Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
    Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic N-acetylation of sulfamethazine and benzidine by human liver: implication for cancer risk?
    Peters JH; Gordon GR; Lin E; Green CE; Tyson CA
    Anticancer Res; 1990; 10(1):225-9. PubMed ID: 2334132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
    Ylitalo P; Auterinen L; Marttinen A; Koivula T
    Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylation phenotype in colorectal carcinoma.
    Ilett KF; David BM; Detchon P; Castleden WM; Kwa R
    Cancer Res; 1987 Mar; 47(5):1466-9. PubMed ID: 3815349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetylator phenotypes in hyperthyroidism.
    Siegmund W; Franke G; Meng S; Gothe P; Meng W
    Int J Clin Pharmacol Ther Toxicol; 1988 Aug; 26(8):397-9. PubMed ID: 3220615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
    William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
    Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic acetylator phenotype in diabetes mellitus.
    Ladero JM; Arrojo A; de Salamanca RE; Gomez M; Cano F; Alfonso M
    Ann Clin Res; 1982 Aug; 14(4):187-9. PubMed ID: 7168549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
    Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
    Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
    Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of isoniazid acetylation phenotypes in North Indians.
    Gupta RC; Nair CR; Jindal SK; Malik SK
    Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):259-64. PubMed ID: 6746149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study.
    Filiadis IF; Georgiou I; Alamanos Y; Kranas V; Giannakopoulos X; Lolis D
    J Urol; 1999 May; 161(5):1672-5. PubMed ID: 10210437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between metabolic phenotype of N-acetylation and bladder cancer.
    Cui X; Guo R; Xu Z; Wang B; Li C
    Chin Med J (Engl); 2000 Apr; 113(4):303-5. PubMed ID: 11775223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of the slow acetylator phenotype with bladder cancer.
    Evans DA; Eze LC; Whibley EJ
    J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Distribution of acetylator phenotypes in the normal Moscow city population and in chronic alcoholism].
    Lil'in ET; Korsunskaia MP; Meksin VA; Drozdov ES; Nazarov VV
    Genetika; 1984 Sep; 20(9):1557-9. PubMed ID: 6542045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylator phenotype in patients with lung carcinoma--a negative report.
    Burgess EJ; Trafford JA
    Eur J Respir Dis; 1985 Jul; 67(1):17-9. PubMed ID: 4054252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.